Thermo Fisher Scientific Inc ($TMO) Stock Forecast: Up 5.1% Today

What is Thermo Fisher Scientific Inc?

Thermo Fisher Scientific (TMO) operates in the scientific research and laboratory equipment industry, known for its advancements in mass spectrometry, AI software, and integrated workflows.

Why is Thermo Fisher Scientific Inc going up?

TMO stock is up 5.1% on Jun 9, 2026 19:55

• Despite a positive market trend, an adjustment in rating to Hold from Buy by a financial institution and uncertainties regarding future growth targets post-2027 may have impacted investor confidence.
• On the other hand, another financial firm's endorsement of TMO's performance emphasized its strong market presence and successful growth strategies through acquisitions, contrasting with the more cautious view of the first institution.
• The recent unveiling of new mass spectrometry platforms and AI software at a notable event by Thermo Fisher Scientific likely boosted market optimism and drove an upward movement in its stock.
• Evaluating TMO alongside other AI companies in the market indicates that investors are comparing potential returns and risks within the sector, which could influence the stock's performance.

TMO Price Chart

TMO Technical Analysis

TMO News

Wolfe Research Downgrades Danaher Corporation (DHR)

Wolfe Research downgraded Danaher Corporation (NYSE:DHR) to Peer Perform from Outperform, citing similar growth to Thermo Fisher, which is "a little cheaper on P/E," and confusion regarding DHR's identity after the Masimo transaction. This comes despite RBC Capital resuming coverage with an Outperform rating and a $200 price target, foreseeing growth recovery driven by improvements in the bioprocess market. While DHR is a significant diagnostics stock, the article suggests certain AI stocks may offer greater upside potential with less downside risk.

https://finance.yahoo.com/sectors/healthcare/articles/wolfe-research-downgrades-danaher-corporation-174141940.html

Why HSBC Turned More Cautious on Thermo Fisher Scientific (TMO)

HSBC downgraded Thermo Fisher Scientific (TMO) to Hold from Buy, lowering its price target due to concerns about the company's growth targets beyond 2027, lower bioprocessing exposure, and near-term organic growth momentum. This contrasts with Wolfe Research's recent Outperform rating, which highlighted Thermo Fisher's strong market position and successful acquisition-led growth strategy. Despite TMO's potential, the article suggests that certain AI stocks might offer greater upside and less downside risk.

https://uk.finance.yahoo.com/news/why-hsbc-turned-more-cautious-025025331.html

Why HSBC Turned More Cautious on Thermo Fisher Scientific (TMO)

HSBC downgraded Thermo Fisher Scientific (TMO) to Hold from Buy, lowering its price target due to concerns about the company's growth targets beyond 2027, lower bioprocessing exposure, and a lack of near-term organic growth momentum. This downgrade occurred just one day after Wolfe Research initiated coverage of TMO with an Outperform rating, highlighting its strong business model as a "serial acquirer." The article suggests that while TMO has potential, other AI stocks might offer higher returns in a shorter timeframe.

https://www.insidermonkey.com/blog/why-hsbc-turned-more-cautious-on-thermo-fisher-scientific-tmo-1777568/

5 Stocks to Buy Before the Next Market Rotation

In this podcast episode, Morningstar's Chief US Market Strategist Dave Sekera and co-host Susan Dziubinski discuss the anticipated SpaceX IPO, current inflation reports, and the Fed meeting. Sekera also provides Morningstar's take on recent earnings from Palo Alto Networks, CrowdStrike, and Broadcom, and analyzes Berkshire Hathaway's latest investments. The hosts conclude with five stock picks—Verizon, Thermo Fisher Scientific, Duke Energy, Realty Income, and Devon Energy—recommended for rebalancing a barbell portfolio.

https://www.morningstar.com/stocks/5-stocks-buy-before-next-market-rotation

Thermo Fisher Scientific Introduces New Mass Spectrometry Platforms and AI Software

Thermo Fisher Scientific has introduced three new mass spectrometry Orbitrap platforms, AI-enabled software, and integrated workflows at the American Society for Mass Spectrometry Conference. These innovations are designed to enhance sample analysis and data interpretation across research, drug development, and safety testing. The new offerings cater to complex samples and large data sets in various environments, including biopharmaceutical and environmental safety applications.

https://clpmag.com/diagnostic-technologies/digital-pathology/analytical-software-systems/thermo-fisher-launches-mass-spectrometry-platforms-ai-software/

Trending Today

Skyworks Solutions Inc. ($SWKS) Stock Forecast: Down 5.1% Today

Cboe Global Markets Inc. ($CBOE) Stock Forecast: Down 8.8% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 5.7% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Down 5.7% Today

Micron Technology Inc. ($MU) Stock Forecast: Down 5.3% Today

DXC Technology Company ($DXC) Stock Forecast: Up 5.3% Today

Moderna Inc. ($MRNA) Stock Forecast: Up 9.5% Today

Take-Two Interactive Software Inc. ($TTWO) Stock Forecast: Up 5.2% Today

KLA-Tencor Corporation ($KLAC) Stock Forecast: Down 5.2% Today

Instacart (Maplebear Inc) ($CART) Stock Forecast: Up 6.1% Today

Thermo Fisher Scientific Inc Price History

29.00.2026 - TMO Stock was down 5.2%

• Thermo Fisher (TMO) experienced a bearish movement despite reporting better-than-expected Q4 CY2025 results, with revenue surpassing analyst estimates and strong performance in its Life Sciences Solutions segment.
• The stock might have faced downward pressure due to profit-taking by investors following the immediate stock increase post-earnings report.
• The overall market sentiment could have been influenced by broader market conditions or sector rotation, leading to the bearish movement in TMO's stock price today.
• It's possible that investors were expecting even stronger guidance or future outlook from the company, causing some disappointment and resulting in the bearish market movement.

23.03.2026 - TMO Stock was down 10.0%

• Thermo Fisher's stock experienced a bearish movement despite beating first-quarter earnings estimates, primarily due to concerns over modest organic growth and a cautious outlook.
• The company's reliance on acquisitions for revenue growth, with organic growth at only 1%, raised investor worries about sustainable future growth prospects.
• The CEO's optimistic comments about benefiting from domestic manufacturing efforts and strategic collaborations were overshadowed by the market's focus on underlying growth challenges and revenue outlook concerns.
• The bearish trend might have been further exacerbated by profit-taking behavior following the recent stock repurchases and dividend increase, as investors reevaluated the company's overall growth trajectory.

23.03.2026 - TMO Stock was down 11.0%

• Thermo Fisher Scientific reported strong first-quarter results with revenue and earnings growth, driven by acquisitions and new product launches.
• Despite beating earnings estimates, the stock experienced a bearish movement due to concerns over modest organic growth and a cautious full-year revenue outlook.
• Investors focused on the company's reliance on acquisitions for revenue increase and the slightly below-consensus full-year revenue guidance, leading to the stock decline.
• The market reaction suggests that while the company's financials are solid, concerns about future organic growth and demand are weighing on investor sentiment, resulting in the bearish movement of the stock.

23.03.2026 - TMO Stock was down 10.5%

• Thermo Fisher Scientific's stock saw a bearish trend due to weaker-than-expected organic growth, which raised concerns about demand despite exceeding revenue and EPS expectations.
• The market reacted negatively to the company's reliance on acquisitions for growth, with organic revenue growth at only 1%, indicating a preference for sustainable core business performance.
• Despite successful capital deployment, new product launches, and strategic partnerships, investors prioritized the quality of underlying business growth over the earnings beat, leading to the stock decline.
• The bearish movement highlights the market's emphasis on sustainable growth and operational excellence rather than short-term financial metrics, impacting Thermo Fisher's stock performance negatively.

02.00.2026 - TMO Stock was up 2.2%

• The global single-use bioprocessing products market is expected to witness substantial growth, with Thermo Fisher Scientific Inc. playing a significant role in the industry's advancement, contributing to the optimistic market trends.
• Noteworthy increases in stakes by Allspring Global Investments Holdings LLC and Ninety One UK Ltd in TMO reflect a growing confidence in the company's future, potentially influencing a rise in the stock's value.
• Despite recent significant insider sales, the company's impressive quarterly earnings report surpassing expectations, coupled with the initiation of a new stock buyback program and quarterly dividend declaration, have likely bolstered investor trust in TMO.
• The collective institutional interest and portfolio adjustments by different investment entities indicate a favorable outlook for TMO, aligning with the current bullish market movement.

18.11.2025 - TMO Stock was down 2.4%

• The decline in TMO stock may be linked to profit-taking by institutional investors actively trading the stock.
• Despite positive updates on strong quarterly earnings and a $5 billion share buyback program, concerns arose among investors due to insider selling by the CEO and COO, potentially contributing to the stock's downward trend.
• Weak performance by West Pharmaceutical Services (WST) in the healthcare sector could have also impacted investor sentiment towards TMO, as some may have shifted away from underperforming healthcare stocks.
• In sum, today's bearish movement in TMO stock seems influenced by profit-taking, insider selling concerns, and broader sector trends affecting investor outlook.

12.01.2026 - TMO Stock was down 5.2%

• Varma Mutual Pension Insurance Co and Cornerstone Investment Partners LLC increased their holdings in TMO, showing confidence in the company's future prospects.
• ING Groep NV and Atria Investments Inc reduced their stakes in TMO, possibly due to profit-taking or portfolio rebalancing.
• The initiation of a $5 billion stock repurchase plan by Thermo Fisher Scientific may have influenced market sentiment, signaling management's belief in the company's undervaluation.
• Despite the mixed institutional activity and insider sales, analysts maintain a "Moderate Buy" rating for TMO, with an average price target of $633.68, reflecting positive quarterly earnings and growth potential.

14.03.2026 - TMO Stock was up 5.0%

• Thermo Fisher Scientific's stock surged 3.6% today, indicating a bullish trend.
• The collaboration with HealthVerity to enhance real-world data capabilities shows the company's commitment to advancing clinical research and evidence generation.
• The undervaluation of TMO compared to its GF Value™ and the strong GF Score™ of 88 highlight positive performance metrics despite insider selling, signaling potential challenges ahead.
• The focus on precision medicine growth through collaborations like PRECISE-SG100K biobank positions TMO well for long-term success in the evolving healthcare landscape.

09.05.2026 - TMO Stock was up 5.1%

• Despite a positive market trend, an adjustment in rating to Hold from Buy by a financial institution and uncertainties regarding future growth targets post-2027 may have impacted investor confidence.
• On the other hand, another financial firm's endorsement of TMO's performance emphasized its strong market presence and successful growth strategies through acquisitions, contrasting with the more cautious view of the first institution.
• The recent unveiling of new mass spectrometry platforms and AI software at a notable event by Thermo Fisher Scientific likely boosted market optimism and drove an upward movement in its stock.
• Evaluating TMO alongside other AI companies in the market indicates that investors are comparing potential returns and risks within the sector, which could influence the stock's performance.

28.04.2026 - TMO Stock was up 8.0%

• Thermo Fisher's stock saw a significant increase of 5.14%, propelled by the company's strong Q1 2026 results that surpassed expectations, leading to a positive revision of their full-year EPS guidance.
• Investor confidence in Thermo Fisher's technological advancements was further reinforced with the introduction of new advanced mass spectrometers at a major conference.
• Despite the optimistic market movement, concerns arise regarding the potential impact on adjusted EPS from the sale of its microbiology business and the overall macroeconomic challenges facing the company. Monitoring Thermo Fisher's strategies to address these obstacles will be crucial for investors.

28.04.2026 - TMO Stock was up 5.5%

• The recent bullish movement in TMO's stock can be linked to its target of achieving a 7% organic revenue compound annual growth rate (CAGR) as disclosed at its recent Investor Day, indicating strong growth potential and investor support.
• While there are concerns about the sustainability of long-term growth, TMO's strategic actions, including the launch of a new bioanalytical and biomarker laboratory in Sweden, underscore its dedication to meeting market needs and strengthening its industry position.
• The announcement of a quarterly cash dividend of $0.47 per common share showcases TMO's financial stability and commitment to shareholders, fostering positive investor sentiment.
• Despite the allure of alternative opportunities in AI stocks for potentially higher short-term returns, TMO's focus on long-term growth and strategic investments positions it well for continued success in the life sciences sector.

28.04.2026 - TMO Stock was up 7.3%

• Thermo Fisher (TMO) showcased its cutting-edge mass spectrometers at a major conference, highlighting its commitment to advancing scientific research and decision-making processes.
• Despite insider selling activity, the company's solid profitability and ambitious 7% annual growth target signal confidence in its future prospects.
• RBC Capital's Sector Perform rating and price objective suggest a balanced view on TMO's performance, acknowledging market improvements while cautioning about long-term growth sustainability.
• The emphasis on meeting increased demand for advanced drug development solutions and strengthening global networks reflects TMO's strategic positioning for growth, despite suggestions of potentially higher returns in certain AI stocks.